Cyclerion Therapeutics (NASDAQ:CYCN) & Genelux (NASDAQ:GNLX) Head-To-Head Contrast

Genelux (NASDAQ:GNLX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Insider & Institutional Ownership

37.3% of Genelux shares are owned by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are owned by institutional investors. 9.3% of Genelux shares are owned by insiders. Comparatively, 13.1% of Cyclerion Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Genelux has a beta of -1.37, suggesting that its share price is 237% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

Profitability

This table compares Genelux and Cyclerion Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-125.58%	-86.03%
Cyclerion Therapeutics	N/A	-77.93%	-61.09%

Valuation and Earnings

This table compares Genelux and Cyclerion Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$170,000.00	444.53	-$28.30 million	($0.97)	-2.27
Cyclerion Therapeutics	$1.62 million	3.63	-$5.26 million	N/A	N/A

Cyclerion Therapeutics has higher revenue and earnings than Genelux.

Analyst Ratings

This is a breakdown of current ratings and price targets for Genelux and Cyclerion Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	0	0	4	0	3.00
Cyclerion Therapeutics	0	0	0	0	N/A

Genelux currently has a consensus target price of $32.33, indicating a potential upside of 1,369.70%. Given Genelux’s higher probable upside, research analysts plainly believe Genelux is more favorable than Cyclerion Therapeutics.

Summary

Cyclerion Therapeutics beats Genelux on 7 of the 10 factors compared between the two stocks.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.